The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Open accessAbstract
Sclerosteosis is an autosomal recessive sclerosing bone dysplasia characterized by progressive skeletal overgrowth. The majority of affected individuals have been reported in the Afrikaner population of South Africa, where a high incidence of the disorder occurs as a result of a founder effect. Homozygosity mapping in Afrikaner families along with analysis of historical recombinants localized sclerosteosis to an interval of approximately 2 cM between the loci D17S1787 and D17S930 on chromosome 17q12-q21. Here we report two independent mutations in a novel gene, termed "SOST." Affected Afrikaners carry a nonsense mutation near the amino terminus of the encoded protein, whereas an unrelated affected person of Senegalese origin carries a splicing mutation within the single intron of the gene. The SOST gene encodes a protein that shares similarity with a class of cystine knot-containing factors including dan, cerberus, gremlin, prdc, and caronte. The specific and progressive effect on bone formation observed in individuals affected with sclerosteosis, along with the data presented in this study, together suggest that the SOST gene encodes an important new regulator of bone homeostasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [17]
Citations
Cites
Bone: Formation by Autoinduction
Urist, M. R. (1965) · Science · doi:10.1126/science.150.3698.893 · Cited by 5,546 · cited 1×
“Although this family of morpho-gens was originally identified on the basis of bone-in-ducing activity (Urist 1965), a number of these factors have been shown to be critical for very early stages of embryogenesis and fetal development.”
Prediction of complete gene structures in human genomic DNA
Burge, C., & Karlin, S. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.0951 · Cited by 4,228 · cited 8×
“The novel variant gene (designated “P50gsc3”) predicted by GENSCAN was located between markers D17S951 and D17S1860 (fig.”
InfluentialA comprehensive genetic map of the human genome based on 5,264 microsatellites
Dib, C., Fauré, S., Fizames, C., Samson, D., Drouot, N., Vignal, A., Millasseau, P., Marc, S., Kazan, J., Seboun, E., et al. (1996) · Nature · doi:10.1038/380152a0 · Cited by 2,928 · cited 3×
“D17S1793, D17S1789, D17S951, and D17S1860 within the critical region bounded by D17S1787 and D17S930, an interval of ∼ 2 cM (Dib et al. 1996) on the cytogenetic border between the chromosomal bands 17q12–q21.”
Bone morphogenetic proteins: multifunctional regulators of vertebrate development.
Hogan, B. L. (1996) · Genes & Development · doi:10.1101/gad.10.13.1580 · Cited by 1,962
Therapeutic Approaches to Bone Diseases
Rodan, G. A., & Martin, T. J. (2000) · Science · doi:10.1126/science.289.5484.1508 · Cited by 1,767 · cited 1×
“Currently there is no effective treatment for the restoration of normal bone mass in individuals with pathologically low skeletal density, and there is a large unmet need for therapy that can increase bone deposition in osteoporosis (Rodan and Martin 2000).”
BackgroundEasy calculations of lod scores and genetic risks on small computers.
Lathrop, M. G., & Lalouel, J.-M. (1984) · Europe PMC (PubMed Central) · Cited by 1,526
Faster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Nonsense-mediated mRNA decayin health and disease
Frischmeyer, P. A. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.10.1893 · Cited by 992 · cited 1×
“The relatively low levels of mutant transcripts observed could be the result of nonsense-mediated mRNA decay, as the inclusion of intronic sequence introduced an in-frame nonsense codon (Frischmeyer and Dietz 1999; Hentze and Kulozik 1999).”
BackgroundHomozygosity Mapping: A Way to Map Human Recessive Traits with the DNA of Inbred Children
Lander, E. S., & Botstein, D. (1987) · Science · doi:10.1126/science.2884728 · Cited by 875
FORMATION AND FUNCTION OF SPEMANN'S ORGANIZER
Harland, R., & Gerhart, J. (1997) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.13.1.611 · Cited by 839 · cited 1×
“In addition, the requirement for the coordinated expression of negative regulators of BMP activity, such as noggin and chordin, as well as members of the dan family, has been well described (Harland and Gerhart 1997; Sasai and De Robertis 1997; Hsu et al. 1998).”
Background
Research works printed but not linked: 3
- Gardner J (1999) Profound childhood deafness in South Africa: a clinical and molecular genetic approach. Ph.D. thesis, University of Cape Town, Cape Town
- Hausen, 1967, Sklerosteose, Vol. 6, 351
- Peitruschka, 1958, Weitere Mitteilungen über die Marmorknochenkrankheit (Albers-Schonbergsche Krankheit) nebst Bemerkungen zur Differentialdiagnose, Klin Monatbl, 132, 509
Cited by
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation
Chen, G., Deng, C., & Li, Y.-P. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.2929 · Cited by 1,756
“SOST sclerosteosis increased bone density (147)”
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708322 · Cited by 1,544
Control of osteoblast function and regulation of bone mass
Harada, S.-I., & Rodan, G. A. (2003) · Nature · doi:10.1038/nature01660 · Cited by 1,444
“Five distinct mutations that lead to SOST inactivation have been identified in families with HBM in South Africa, Senegal, Brazil and the United State”
BackgroundRegulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Mechanisms of bone development and repair
Salhotra, A., Shah, H. N., Levi, B., & Longaker, M. T. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-00279-w · Cited by 1,186
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
“disorders Van Buchem’s disease and sclerosteosis (91, 92),”
BackgroundBuilding strong bones: molecular regulation of the osteoblast lineage
Long, F. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3254 · Cited by 1,141
Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y.-H., Duncan, E. L., Ntzani, E. E., Oei, L., Albagha, O. M. E., Amin, N., Kemp, J. P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2249 · Cited by 1,174
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Self-citationLDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling:Arrows point the way
He, X., Semenov, M., Tamai, K., & Zeng, X. (2004) · Development · doi:10.1242/dev.01117 · Cited by 1,044
“Sclerosterosis is a progressive bone dysplasia associated with loss-of-function mutations of a secreted protein referred to as SOST (Balemans et al., 2001; Brunkow et al., 2001).”
BackgroundThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Self-citationLi, X., Ominsky, M. S., Niu, Q.-T., Sun, N., Daugherty, B., D'Agostin, D., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 936
“Mutations in a previously undescribed gene, SOST, were identified by positional cloning as being responsible for causing sclerosteosis.((3,4)) Sclerostin, the pro-”
Backgroundvan Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L., de Wilt, E., Karperien, M., Hamersma, H., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 892
“Alternatively, and perhaps more likely because of the presence of a putative secretion signal in sclerostin (16), the transport may occur extracellularly from lacuna to lacuna.”
BackgroundInfluentialSelf-citationBone Morphogenetic Proteins, Their Antagonists, and the Skeleton
Canalis, E., Economides, A. N., & Gazzerro, E. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0023 · Cited by 863
Wnt signaling in development and tissue homeostasis
Steinhart, Z., & Angers, S. (2018) · Development · doi:10.1242/dev.146589 · Cited by 821
“…example is mutations discovered in SOST (sclerostin), a negative regulator of LRP5/6 that was found to be causally linked to high bone density pathology via loss-of-function mutations (Brunkow et al., 2001) or mutations that decrease its expression (Balemans et al., 2002; Loots et al., 2005).”
BackgroundSingle-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
“Individuals who are homozygous for null mutations in SOST, the gene that encodes sclerostin, have sclerosteosis.((8,9)) This syndrome is characterized by progressive bone thickening that results in significant increases in bone mass and bone mineral density (BMD) throughout the skeleton.”
BackgroundLi, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Osteoclast–osteoblast communication
Matsuo, K., & Irie, N. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.027 · Cited by 780
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Development of the Endochondral Skeleton
Long, F., & Ornitz, D. M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008334 · Cited by 663
“Further supporting the role of LRP5 signaling in bone formation, loss-of-function or loss-of-expression mutations in Sost, which are expected to enhance LRP5 signaling, result in the bone-thickening diseases known as sclerosteosis or van Buchem disease, respectively (Balemans et al. 2001, 2002; Brunkow et al. 2001; St…”
BackgroundIdentification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698
Bone morphogenetic proteins: a critical review
Bragdon, B., Moseychuk, O., Saldanha, S., King, D., Julian, J., & Nohe, A. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.003 · Cited by 691
Mechanisms of Anabolic Therapies for Osteoporosis
Canalis, E., Giustina, A., & Bilezikian, J. P. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067395 · Cited by 668
Role of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 641
Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 641
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 628
“Sclerostin, encoded by the Sost gene, is a secreted cysteine-knot protein among the DAN family, which includes proteins antagonize BMP and Wnt signaling.((11)) Sclerostin has emerged as a potent inhibitor of bone growth.”
BackgroundSecreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
“SOST is highly expressedinosteoblastsandosteocytes, andloss-offunction mutations or down-regulation of SOST are responsible for two rare forms of autosomal recessive severe craniotubular hyperostoses, sclerosteosis (Balemans et al. 2001; Brunkow et al. 2001), and van Buchem disease (Balemans et al.”
BackgroundSOST is a target gene for PTH in bone
Keller, H., & Kneissel, M. (2005) · Bone · doi:10.1016/j.bone.2005.03.018 · Cited by 616
“Most importantly, SOST loss-of-function mutations in humans are the cause of the autosomal recessive bone dysplasias Sclerosteosis and Van Buchem disease, which are characterized by massive bone overgrowth throughout life and increased bone strength and serum markers of bone formation [21,23,30,31].”
BackgroundExtracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators
Balemans, W., & Van Hul, W. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0779 · Cited by 621
The cell biology of bone metabolism
Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Bénichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/368277 · Cited by 568
“The increased bone formation in sclerosteosis (SOST [MIM 269500]) and in Van Buchem disease (VBCH [MIM 239100]) turned out to be due to loss-of-function mutations of the SOST gene, most likely increasing bone morphogenetic protein signaling (Balemans et al. 2001, 2002; Brunkow et al. 2001).”
BackgroundPederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
“Sclerostin is the product of the SOST gene, which is mutated and down-regulated in patients with sclerosteosis and van Buchem’s disease (22, 23).”
BackgroundDeletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass
Morvan, F., Boulukos, K., Clément-Lacroix, P., Roman, S. R., Suc-Royer, I., Vayssière, B., Ammann, P., Martin, P., Pinho, S., Pognonec, P., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060311 · Cited by 524
Drug development in the era of precision medicine
Dugger, S. A., Platt, A., & Goldstein, D. B. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.226 · Cited by 493
Hellemans, J., Preobrazhenska, O., Willaert, A., Debeer, P., Verdonk, P. C. M., Costa, T., Janssens, K., Menten, B., Roy, N. V., Vermeulen, S. J. T., et al. (2004) · Nature Genetics · doi:10.1038/ng1453 · Cited by 472
“Loss-of-function mutations in SOST , encoding the extracellular BMP antagonist sclerostin, lead to sclerosteosi”
BackgroundTu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2012) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 459
“Loss of SOST expression in humans causes the high bone mass disorders Van Buchem’s disease [7] and sclerosteosis [8].”
Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis
Langdahl, B., Ferrari, S., & Dempster, D. W. (2016) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x16670154 · Cited by 432
“Abnormalities in bone remodeling cause bone loss or bone gain and are the basis of low and high bone-mass syndromes [Brunkow et al. 2001; Johnson et al. 1997; Motyckova and Fisher, 2002].”
BackgroundGoldberg, Y., MacFarlane, J., MacDonald, M., Thompson, J., Dube, M., Mattice, M., Fraser, R., Young, C., Hossain, S., Pape, T., et al. (2007) · Clinical Genetics · doi:10.1111/j.1399-0004.2007.00790.x · Cited by 455
“For example, a novel approach for the treatment of osteoporosis in the general population was derived from the identification of the gene which, when disrupted, causes sclerosteosis (31, 32), a disorder of increased bone density.”
BackgroundRole and mechanism of action of sclerostin in bone
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 443
“Sclerostin was originally described as a glycoprotein of ~27 KDa that is secreted in a monomeric form (77;78).”
Lrp5 functions in bone to regulate bone mass
Cui, Y., Niziolek, P. J., MacDonald, B. T., Zylstra, C. R., Alenina, N., Robinson, D. R., Zhong, Z., Matthes, S., Jacobsen, C. M., Conlon, R. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2388 · Cited by 453
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
“2003), and these documented cases predominantly correspond to large chromosomal aberrations (Curtin et al. 1985; Curtin and Kan 1988; Cimbora et al. 2000; Kleinjan et al. 2001; Chuzhanova et al. 2003).”
BackgroundOminsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
The role of Dickkopf-1 in bone development, homeostasis, and disease
Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., & Shaughnessy, J. D. (2009) · Blood · doi:10.1182/blood-2008-03-145169 · Cited by 408
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 397
“(1,3–6) The biologic importance of sclerostin in humans is highlighted by sclerosteosis and van Buchem disease, two genetic diseases associated with markedly increased bone mass.(7–10) Sclerosteosis is caused by a mutation in the gene encoding sclerostin, SOST, that leads to improper splicing of the SOSTmRNA,(7,8) whe…”
BackgroundUpdate on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Ralston, S. H., & Uitterlinden, A. G. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0044 · Cited by 376
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O'Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortazar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 390
Osteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
“Loss of SOST expression in humans causes the high–bone mass disorders Van Buchem’s disease [16] and sclerosteosis [17].”
WNT1 Mutations in Early-Onset Osteoporosis and Osteogenesis Imperfecta
Laine, C. M., Joeng, K. S., Campeau, P. M., Kiviranta, R., Tarkkonen, K., Grover, M., Lu, J. T., Pekkinen, M., Wessman, M., Heino, T. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215458 · Cited by 365
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
Bezooijen, R. L. V., Dijke, P. T., Papapoulos, S. E., & G.M. Löwik, C. W. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.005 · Cited by 367
“In 2001, two groups independently identified mutations in a novel gene they called SOST as the cause of sclerosteosis [18,19].”
BackgroundInfluentialOsteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures
Movérare-Skrtic, S., Henning, P., Liu, X., Nagano, K., Saito, H., Börjesson, A. E., Sjögren, K., Windahl, S. H., Farman, H., Kindlund, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3654 · Cited by 361
Genetic regulation of bone mass and susceptibility to osteoporosis
Ralston, S. H., & de Crombrugghe, B. (2006) · Genes & Development · doi:10.1101/gad.1449506 · Cited by 364
“1999), and positional cloning studies identified recessive loss-of-function mutations in Sclerostin (SOST) gene as the cause of Sclerosteosis in 2001 (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundBone Morphogenetic Proteins in Vascular Calcification
Hruska, K. A., Mathew, S., & Saab, G. (2005) · Circulation Research · doi:10.1161/01.res.00000175571.53833.6c · Cited by 360
New sequence variants associated with bone mineral density
Styrkarsdottir, U., Halldorsson, B. V., Gretarsdottir, S., Gudbjartsson, D. F., Walters, G. B., Ingvarsson, T., Jonsdottir, T., Saemundsdottir, J., Snorradóttir, S., Center, J. R., et al. (2009) · Nature Genetics · doi:10.1038/ng.284 · Cited by 362
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
Building bone to reverse osteoporosis and repair fractures
Khosla, S., Westendorf, J. J., & Oursler, M. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33612 · Cited by 353
“Sclerostin is the product of the SOST gene, which is mutated and downregulated in patients with sclerosteosis and van Buchem disease (67, 68), diseases characterized by high bone density.”
Ellies, D. L., Viviano, B., McCarthy, J., Rey, J.-P., Itasaki, N., Saunders, S., & Krumlauf, R. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060810 · Cited by 350
“It has been proposed that the recessive HBM phenotype seen in patients with sclerosteosis is caused by the potential role of SOST as a BMP inhibitor.((14,15,17,36)) A much higher concentration of Sost is required for its role as a BMP antagonist than its ability to inhibit Wnt-mediated ALP induction,((36)) suggesting…”
BackgroundMethodInfluentialSclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
“In humans, SOST mRNA is expressed in the heart, aorta, and liver, with high levels in the kidney [16, 17, 26, 27]; but no sclerostin protein has”
BackgroundManolagas, S. C., & Almeida, M. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0259 · Cited by 330
Notch Signaling and the Skeleton
Zanotti, S., & Canalis, E. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1002 · Cited by 321
Wise, a context-dependent activator and inhibitor of Wnt signalling
Itasaki, N., Jones, C. M., Mercurio, S., Rowe, A., Domingos, P. M., Smith, J. C., & Krumlauf, R. (2003) · Development · doi:10.1242/dev.00674 · Cited by 321
“%) to Sclerostin (SOST), identified by positional cloning of the gene mutated in sclerosteosis (Brunkow et al., 2001).”
BackgroundCirculating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2186 · Cited by 311
“(28) and Van Buchem’s disease (29), murine sclerostin”
BackgroundA Wnt canon orchestrating osteoblastogenesis
Hartmann, C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.01.001 · Cited by 314
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C., Hu, S., Kramer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Ramos Fuentes, F. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 301
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
The BMP antagonist noggin regulates cranial suture fusion
Warren, S. M., Brunet, L. J., Harland, R. M., Economides, A. N., & Longaker, M. T. (2003) · Nature · doi:10.1038/nature01545 · Cited by 303
Wnt signaling and cellular metabolism in osteoblasts
Karner, C. M., & Long, F. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2425-5 · Cited by 295
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O'Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 287
Staehling‐Hampton, K., Proll, S., Paeper, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D., Schatzman, R. C., Beighton, P., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10401 · Cited by 294
“, 2001], and thereafter the sclerosteosis gene, termed SOST, was identified [Brunkow et al., 2001; Balemans et al., 2001].”
BackgroundMethodInfluentialSelf-citationThe role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Tu, X., Delgado-Calle, J., Condon, K. W., Maycas, M., Zhang, H., Carlesso, N., Taketo, M. M., Burr, D. B., Plotkin, L. I., & Bellido, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409857112 · Cited by 276
van Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H., Vrieling, H., Papapoulos, S. E., ten Dijke, P., et al. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061002 · Cited by 283
“Originally, sclerostin was suggested to inhibit bone formation by antagonizing BMP activity((5)) However, whereas consistent findings have been reported with regard to the inhibitory effect of sclerostin on late BMP responses such as ALP activity, contradictory findings have been published on the direct BMP response o…”
BackgroundKamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. (2008) · Development · doi:10.1242/dev.025825 · Cited by 275
“Loss-of-function and hypomorphic mutations in SOST cause sclerosteosis (Balemans et al., 2001; Brunkow et al., 2001) and Van Buchem disease (Balemans et al., 2002; Staehling-Hampton et al., 2002), respectively, and bone mass is increased in these disorders, similar to Sost KO mouse (Li et al.,…”
Kusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., Thesleff, I., & Itoh, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301716200 · Cited by 274
Laurikkala, J., Kassai, Y., Pakkasjärvi, L., Thesleff, I., & Itoh, N. (2003) · Developmental Biology · doi:10.1016/j.ydbio.2003.08.011 · Cited by 270
Ominsky, M. S., Li, C., Li, X., Tan, H. L., Lee, E., Barrero, M., Asuncion, F. J., Dwyer, D., Han, C.-Y., Vlasseros, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
Mohammed, M. K., Shao, C., Wang, J., Wei, Q., Wang, X., Collier, Z., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 259
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
“3b) and (4) slightly Fracture callus BV/TV”
Extracellular BMP-antagonist regulation in development and disease: tied up in knots
Walsh, D. W., Godson, C., Brazil, D. P., & Martin, F. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.008 · Cited by 246
Regulation of Bone Remodeling by Parathyroid Hormone
Wein, M. N., & Kronenberg, H. M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031237 · Cited by 241
“This rare Mendelian skeletal dyscrasia is caused by mutations in SOST, which encodes the protein sclerostin, an osteocyte-specific secretion that may act as a paracrine inhibitor of WNT signaling (Brunkow et al. 2001).”
BackgroundWnt and the Wnt signaling pathway in bone development and disease
Wang, Y. (2014) · Frontiers in Bioscience · doi:10.2741/4214 · Cited by 248
“Sclerosteosis, an autosomal recessive sclerosing bone dysplasia is due to the loss of the SOST expression (108, 244).”
BackgroundEffects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Drake, M. T., Srinivasan, B., Mödder, U. I., Peterson, J. M., McCready, L. K., Riggs, B. L., Dwyer, D., Stolina, M., Kostenuik, P., & Khosla, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0720 · Cited by 251
Parathyroid hormone (PTH)–induced bone gain is blunted in SOST overexpressing and deficient mice
Kramer, I., Loots, G. G., Studer, A., Keller, H., & Kneissel, M. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090730 · Cited by 247
“Moreover, patients afflicted by sclerosteosis (MIM 269500)((22,23)) or van Buchem disease (MIM 239100)((24,25)) display lifelong bone overgrowth and a high bone mass phenotype with strongly increased bone mineral mass, density, and strength owing to loss of SOST expression.”
BackgroundOsteocyte control of osteoclastogenesis
O'Brien, C. A., Nakashima, T., & Takayanagi, H. (2013) · Bone · doi:10.1016/j.bone.2012.08.121 · Cited by 235
Control of the SOST Bone Enhancer by PTH Using MEF2 Transcription Factors
Leupin, O., Kramer, I., Collette, N. M., Loots, G. G., Natt, F., Kneissel, M., & Keller, H. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070804 · Cited by 246
“In some experiments, stimulation with human PTH(1-34) was performed 8 h after transfection.”
BackgroundMethodInfluentialVascular calcification: from pathophysiology to biomarkers
Evrard, S., Delanaye, P., Kamel, S., Cristol, J.-P., Cavalier, E., Arnaud, J., Zaoui, P., Carlier, M. C., Laville, M., Fouque, D., et al. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.08.034 · Cited by 245
“Sclerostin is an osteocyte-specific glycoprotein and is considered as a potent inhibitor of bone formation [194,195].”
BackgroundMoustafa, A., Sugiyama, T., Prasad, J., Zaman, G., Gross, T. S., Lanyon, L. E., & Price, J. S. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1656-4 · Cited by 241
“[18, 19] or van Buchem disease [20, 21].”
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
Sutherland, M. K., Geoghegan, J. C., Yu, C., Turcott, E., Skonier, J. E., Winkler, D. G., & Latham, J. A. (2004) · Bone · doi:10.1016/j.bone.2004.05.023 · Cited by 238
Self-citationInvolvement of WNT/β-catenin Signaling in the Treatment of Osteoporosis
Rossini, M., Gatti, D., & Adami, S. (2013) · Calcified Tissue International · doi:10.1007/s00223-013-9749-z · Cited by 236
“Mutations in the SOST gene encoding SOST result in two different diseases well known for decades: the sclerosteosis syndrome, which is characterized by cortical hyperostosis and syndactyly [44], and van Buchem disease, which is similarly characterized by cortical hyperostosis and cranial nerve entrapment, often requir…”
BackgroundCharacterization of the Structural Features and Interactions of Sclerostin
Veverka, V., Henry, A. J., Slocombe, P. M., Ventom, A., Mulloy, B., Muskett, F. W., Muzylak, M., Greenslade, K., Moore, A., Zhang, L., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m807994200 · Cited by 233
Metadata
- Authors
- Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., Alisch, R. S., Gillett, L., Colbert, T., Tacconi, P., Galas, D., Hamersma, H., Beighton, P., & Mulligan, J. T.
- Affiliations
- University of Cape Town (ZA)
- University of Cagliari (IT)
- Corresponding author
- Brunkow, Mary E.
- ORCID
- Venue
- The American Journal of Human Genetics
- Publisher
- Elsevier BV
- Published
- 2001-03
- Volume
- 68
- Issue
- 3
- Pages
- 577-589
- ISSN
- 0002-9297 (ISSN-L)
- PMC
- PMC1274471
- OpenAlex
- W2037750372
- Cited by
- 1,011
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 32 · 2023: 27 · 2022: 36 · 2021: 53 · 2020: 52 · 2019: 46 · 2018: 50 · 2017: 56 · 2016: 65 · 2015: 61 · 2014: 58 · 2013: 60 · 2012: 56
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 4523 d)
- Locations
- The American Journal of Human Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Connective tissue disorders research
- Keywords
- sclerosteosis, SOST gene, skeletal dysplasia, cystine knot proteins, bone homeostasis, skeletal overgrowth, nonsense mutation, splicing mutation, founder effect, Afrikaner population, bone formation regulation
- MeSH terms
- Amino Acid Sequence, Animals, Base Sequence, Bone Diseases, Chromosome Mapping, Chromosomes, Human, Pair 17, Consanguinity, Cystine, Female, Genetic Markers, Homozygote, Humans, Male, Molecular Sequence Data, Netherlands, Pedigree, Proteins, Recombination, Genetic, Sclerosis, Senegal, South Africa, Conserved Sequence, Alternative Splicing, Bone Morphogenetic Proteins, Mutation, Missense, Black People, White People, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.